Caplin Point Laboratories Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/l9bs88z6tjc4moil8353bzik.pdf

Key Takeaways


US Business: The Label Bet Paying Off

Vivek Partheeban: "This goes to show that, this was a decision, in hindsight, was a good one."

Pipeline & Facilities: Building for FY28

C.C. Paarthipan: "If you look at actually injectable facilities whether it is in China or US, always big boys game. In two years, we will be in a position to complete 14 to 15 lines exporting products to US, which is of course, it's not that easy, and we'll be one among the maybe three or four from India."

Margins & Cost Structure


Latin America: The Next Growth Vector


Operating Model & Competitive Positioning

C.C. Paarthipan: "In pharma manufacturing, non-compliance is not a learning failure or a training failure, it's an execution visibility failure."

Guidance & Commitments

CommitmentSpecificsTimeline
FDA approvalsTen pending products to clear reviewNext few months
Acquired ANDA commercializationFourteen acquired ANDAs brought to marketSometime in the next year
Phase 3 facility operationalAt least five of eight lines activeEarly next year
Oncology injectable filingsFirst few products filedEnd of this year
Oncology injectable market entrySome products reach market via PAS routeLate this year or early next year
Oncology facility commercialsFacility starts generating revenueNext two months
Vizag API DMF filingFirst DMF filed from Vizag siteEnd of this year
Blow-fill-seal approvalsFirst products approvedLate FY27 / FY28
Ophthalmic/PFS approvalsTwelve to thirteen products up for approvalEnd of next year
Receivables normalizationBack to 120-day benchmarkBy March, or June if not
Capex completionRemaining manufacturing capex spentNext 12–18 months
Mexico facilityInvestment of ₹100–125 cr; immediate market entry on completionNo date given
Chile top-5 market$10–$15 million annual revenueNext 2–3 years
PAT margin26–29% sustainedOngoing
Tax rate20–21%Coming years

Key Metrics

MetricQ3 FY26
Revenue growth10.6% YoY
Total income growth11.2% YoY
COGS growth9% YoY, despite increase in turnover
COGS as % of revenue39%, down from 43% three years ago
Opex growth6% YoY, below revenue growth
Opex as % of total revenue24.46%, vs 25.62% in corresponding period and 27% in FY24
EBITDA margin38.5%, vs 36.5% in corresponding period
PBT₹589 cr, +17.8% YoY; 35.2% of revenue
PAT₹477 cr, +20.5% YoY; 28.5% of revenue vs 26.3% last year
Net worth₹3,338 cr as of December
Cash and cash equivalents₹1,381 cr, vs ₹1,180 cr after ₹180 cr capex
Cash flow from operations₹368 cr for nine months, vs ₹284 cr in corresponding period
Free cash flow₹188 cr for nine months, after ₹180 cr capex
Receivables days121 days, vs 118 days
Inventory67% of turnover including transit goods; 55% in warehouses, 12% in transit
US label revenueNearly $10 million since inception last year
CSL consolidated EBITDA (Q3)₹31.09 cr
US market revenue (9 months)₹323 cr
US market PBT margin (9 months)34% (per an analyst's math)
Product revenue vs milestone/profit share mix75:25
ANDAs approved under Caplin's name~65 expected within a short period
ANDAs acquired from outside~14 over the last few months
Average ANDA approval timeline14–15 months, vs industry ~20 months
Capex already spent (of ₹1,000 cr plan)₹385 cr; ₹153 cr capitalized, ₹124 cr WIP, ₹88.54 cr advances
Remaining capex timeline12–18 months
Tax rate20%–21%